Scenesse

(Afamelanotide)

Scenesse

Drug updated on 11/14/2023

Dosage FormImplant (subcutaneous: 16 mg)
Drug ClassMelanocortin 1 receptor (MC1-R) agonists
Ongoing and Completed StudiesClinicalTrials.gov

Indication

  • Indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

Product Monograph / Prescribing Information

Document TitleYearSource
Scenesse (afamelanotide) Prescribing Information.2020Clinuvel Inc., Burlingame, CA

Systematic Reviews / Meta-Analyses